DR. NEAL EPSTEIN, M.D.
Osteopathic Medicine at Ashboro Ct, Bethesda, MD
License number
Maryland D0031096
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
8005 Ashboro Ct, Bethesda, MD 20815
Phone
(301) 219-2299
Personal information
See more information about NEAL EPSTEIN at radaris.comName
Address
Phone
8005 Ashboro Ct, Chevy Chase, MD 20815
8005 Ashboro Ct, Chevy Chase, MD 20815
Silver Spring, MD
Professional information
Dr. Neal D Epstein, Chevy Chase MD - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
8005 Ashboro Ct, Chevy Chase 20815
(301) 219-2299 (Phone)
(301) 219-2299 (Phone)
Certifications:
Internal Medicine, 1983
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Rush University
Rush University
Cardiac Myosin Light Chain Kinase-Specific Antibodies And Methods Of Detecting
US Patent:
7824682, Nov 2, 2010
Filed:
Apr 11, 2008
Appl. No.:
12/101812
Inventors:
Neal D. Epstein - Chevy Chase MD, US
Shahin Hassanzadeh - Fairfax VA, US
Steve O. Winitsky - Alexandria VA, US
Julien S. Davis - Baltimore MD, US
Shahin Hassanzadeh - Fairfax VA, US
Steve O. Winitsky - Alexandria VA, US
Julien S. Davis - Baltimore MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 39/395, C07K 16/40, G01N 33/53
US Classification:
4241461, 435 74, 53038826
Abstract:
The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction.
Cardiac Myosin Light Chain Kinase Polypeptide, Encoding Nucleic Acid, And Methods Of Use
US Patent:
7375185, May 20, 2008
Filed:
Sep 12, 2001
Appl. No.:
10/380236
Inventors:
Neal D. Epstein - Chevy Chase MD, US
Shahin Hassanzadeh - Manassas VA, US
Steven Winitsky - Bethesda MD, US
Julien S. Davis - Baltimore MD, US
Shahin Hassanzadeh - Manassas VA, US
Steven Winitsky - Bethesda MD, US
Julien S. Davis - Baltimore MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C07K 1/00
US Classification:
530350, 530300, 435 71, 514 2, 514 12
Abstract:
The present disclosure provides a cDNA, protein sequence, and genomic structure of the human cardiac isoform of myosin light chain kinase (cMLCK), and describes mutations in the cMLCK gene that are associated with cardiac dysfunction. Methods are provided for identifying individuals who can harbor mutations in the cMLCK gene, or carry alleles that can predisposed them to cardiac dysfunction. Disclosed also is a significant role for cMLCK in modulating cardiac contractility. The cMLCK protein is shown herein to reduce the amplitude of stretch activation and increase the tension production, a property of muscle which has heretofore had an unknown role in cardiac contraction. Moreover, the cMLCK protein is shown to be regionally distributed in the heart, thereby having differential effects on contractility and stretch activation. Methods herein are provided to exploit this effect of cMLCK, to treat individuals who have or are prone to cardiac dysfunction. In addition, methods are provided to identify agents that modulate cMLCK activity, thereby having potential therapeutic importance in the treatment of cardiac dysfunction.
Stem Cells That Transform To Beating Cardiomyocytes
US Patent:
2003008, May 1, 2003
Filed:
Oct 22, 2001
Appl. No.:
10/003400
Inventors:
Neal Epstein - Chevy Chase MD, US
Thiru Gopal - North Potomac MD, US
Steve Winitsky - Bethesda MD, US
Shahin Hassanzadeh - Fairfax VA, US
Thiru Gopal - North Potomac MD, US
Steve Winitsky - Bethesda MD, US
Shahin Hassanzadeh - Fairfax VA, US
Assignee:
The Government of the United States of America
International Classification:
A61K048/00, C12N005/06, C12N005/08
US Classification:
424/093210, 435/372000, 435/354000
Abstract:
Disclosed herein is a novel isolated population of stem cells, called spoc cells, that can be induced, either in vivo or in vitro, to differentiate into cardiomyocytes. Methods are disclosed herein to differentiate the spoc cells, and to utilize these spoc cells for screening agents that affect cardiomyocytes. Methods are also provided herein to utilize spoc cells in therapeutic applications for the treatment of myocardial defects, such as areas of ischemic or traumatic damage.
Stem Cells That Transform To Beating Cardiomyocytes
US Patent:
2005005, Mar 17, 2005
Filed:
Jun 7, 2004
Appl. No.:
10/863004
Inventors:
Neal Epstein - Chevy Chase MD, US
Thiru Gopal - North Potomac MD, US
Steve Winitsky - Bethesda MD, US
Shahin Hassanzadeh - Fairfax VA, US
Thiru Gopal - North Potomac MD, US
Steve Winitsky - Bethesda MD, US
Shahin Hassanzadeh - Fairfax VA, US
International Classification:
A61K048/00, C12N005/06, C12N005/08, C12N015/86
US Classification:
424093210, 435456000, 435366000, 435354000
Abstract:
Disclosed herein is a novel isolated population of stem cells, called spoc cells, that can be induced, either in vivo or in vitro, to differentiate into cardiomyocytes. Methods are disclosed herein to differentiate the spoc cells, and to utilize these spoc cells for screening agents that affect cardiomyocytes. Methods are also provided herein to utilize spoc cells in therapeutic applications for the treatment of myocardial defects, such as areas of ischemic or traumatic damage.
Stem Cells That Transform To Beating Cardiomyocytes
US Patent:
2007021, Sep 13, 2007
Filed:
May 10, 2007
Appl. No.:
11/747060
Inventors:
Neal Epstein - Chevy Chase MD, US
Thiru Gopal - North Potomac MD, US
Steve Winitsky - Bethesda MD, US
Shahin Hassanzadeh - Fairfax VA, US
Thiru Gopal - North Potomac MD, US
Steve Winitsky - Bethesda MD, US
Shahin Hassanzadeh - Fairfax VA, US
International Classification:
A61K 35/34, C12N 5/02, C12Q 1/02
US Classification:
424569000, 435029000, 435325000, 435383000, 435384000
Abstract:
Disclosed herein is a novel isolated population of stem cells, called spoc cells, that can be induced, either in vivo or in vitro, to differentiate into cardiomyocytes. Methods are disclosed herein to differentiate the spoc cells, and to utilize these spoc cells for screening agents that affect cardiomyocytes. Methods are also provided herein to utilize spoc cells in therapeutic applications for the treatment of myocardial defects, such as areas of ischemic or traumatic damage.
Monoclonal Antibody That Specifically Binds Stem Cells And Its Use
US Patent:
2008009, Apr 24, 2008
Filed:
Apr 25, 2005
Appl. No.:
11/578891
Inventors:
Neal Epstein - Chevy Chase MD, US
Steve Winitsky - Bethesda MD, US
Thiru Gopal - North Potomac MD, US
Shahin Hassanzadeh - Fairfax VA, US
Steve Winitsky - Bethesda MD, US
Thiru Gopal - North Potomac MD, US
Shahin Hassanzadeh - Fairfax VA, US
Assignee:
THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS - Rockville MD
International Classification:
A61K 48/00, A61P 25/00, C12N 5/02, C12N 5/04, G01N 33/53
US Classification:
424093200, 435368000, 435378000, 435383000, 435395000, 435007210
Abstract:
Antibodies are disclosed herein that bind Spoc cells. In one embodiment the antibodies are monoclonal antibodies. The use of antibodies that bind Spoc cells to identify and/or isolate a sub-population of Spoc cells is also disclosed. In one embodiment, a method for treating a neurologic disorder is provided. The method includes administering a sub-population of Spoc cells and/or and neuronal cells differentiated from Spoc cells to treat a neurologic disorder.